Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.

Abstract

Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of approximately 5,000. As with the other low molecular weight heparins, dalteparin has certain advantages over unfractionated heparin (UFH) most important of which are improved bio-availability by subcutaneous injection, a prolonged antithrombotic activity which is highly correlated with body weight permitting the once daily administration of the drug. Other possible advantages of LMWH including dalteparin include a lower incidence of heparin induced thrombocytopenia and thrombosis and decreased tendency to produce osteopenia on prolonged administration. Dalteparin has been subjected to a large number of well designed randomised clinical trials for the prevention and treatment of venous thromboembolism. Based on data from the randomised clinical trials, dalteparin has been approved internationally for a wide spectrum of clinical indications.

• Authors: Graham F Pineo, Russell D Hull
• Journal: European journal of medical research (Eur J Med Res) Vol. 9 Issue 4 Pg. 215-24 (Apr 30 2004) ISSN: 0949-2321 [Print] England
• PMID: 15210402 (Publication Type: Journal Article, Review)

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• Dalteparin

Topics

• Anticoagulants (therapeutic use)
• Blood Coagulation (drug effects)
• Coronary Disease (complications)
• Dalteparin (pharmacokinetics, pharmacology, therapeutic use)
• Heparin, Low-Molecular-Weight (therapeutic use)
• Humans
• Molecular Weight
• Neoplasms (drug therapy, surgery)
• Surgical Procedures, Operative
• Thromboembolism (drug therapy, prevention & control)